Should I buy Astrana Health, Inc. (ASTH) stock or is it too late?
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
Firm-by-firm track record on Astrana Health, Inc.
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Stifel | 20 % | -29.6 % | 5 | $56 +48% |
✅ Reasons to believe
- 100% of analysts rate it a buy (Buy consensus, 7 ratings) — a sign of market conviction.
- Median price target $53, i.e. +40% from the current price ($38).
- The most reliable firm on ASTH, BTIG (50% hit rate, 2 scored calls), targets $65 (call made on July 14, 2026, maturing on July 14, 2027) (+72%) in its most recent call, and $45 (call made on November 7, 2025, maturing on November 7, 2026) (+19%) in the one coming due soonest.
⚠️ Reasons to hesitate
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
- A near-unanimous consensus leaves little room for positive surprise — a lot of optimism is already baked in.
The analyst consensus on ASTH
Median target $53 (+40%) · 7 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Astrana Health, Inc. now?
We won't decide for you. The facts: 100% of analysts rate it a buy, median target $53 (+40%), and BTIG (most reliable on ASTH, 50%) targets $65. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Astrana Health, Inc.?
Not according to analysts: the median target ($53) is still +40% above the current price ($38) (most reliable on ASTH: BTIG, 50%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Astrana Health, Inc. still worth investing in?
It depends on the gap between the price ($38) and its estimated value: analysts target $53 on median (+40%), with 100% buys (most reliable on ASTH: BTIG, 50%). Cross-check with their real reliability on ASTH and the cautions above. Information, not advice.
What's the main risk in buying ASTH?
A 12-month target is not a guaranteed path: the price can fall in the meantime.
→ Go deeper: the full Astrana Health, Inc. profile (consensus, analyst reliability, price target, performance).